Uncategorized

FDA rejects ITM Isotope’s radiopharma therapy over manufacturing issues

Published

on

ITM Isotope Technologies plans on resubmitting its advanced cancer radiopharma therapy to the FDA after addressing the agency’s concerns.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version